S
Scharla Estep
Researcher at National Institutes of Health
Publications - 7
Citations - 350
Scharla Estep is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Canarypox & Immunization. The author has an hindex of 7, co-authored 7 publications receiving 339 citations. Previous affiliations of Scharla Estep include Rush University Medical Center.
Papers
More filters
Journal ArticleDOI
Safety and Immunogenicity of a Heptavalent Pneumococcal Conjugate Vaccine in Infants With Human Immunodeficiency Virus Type 1 Infection
Sharon Nachman,Soyeon Kim,James C. King,Elaine J. Abrams,David M. Margolis,Ann Petru,William T. Shearer,Elizabeth Smith,Jack Moye,Suzette Blanchard,Elizabeth Hawkins,Pamela Bouquin,Peter E. Vink,Mindy Benson,Scharla Estep,Frank Malinoski +15 more
TL;DR: This study demonstrates that heptavalent PCV was well tolerated and not associated with vaccine-associated adverse reactions, and this vaccine was immunogenic in the infant with HIV infection.
Journal ArticleDOI
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)
Jonathan D. Fuchs,Ian Frank,Marnie Elizaga,Mary Allen,Nicole Frahm,Nidhi Kochar,Sue Li,Srilatha Edupuganti,Spyros A. Kalams,Georgia D. Tomaras,Rebecca L. Sheets,Michael Pensiero,Marc Tremblay,Terry J. Higgins,Theresa E. Latham,Michael A. Egan,David K. Clarke,John H. Eldridge,Mark J. Mulligan,Nadine Rouphael,Scharla Estep,Kyle Rybczyk,Deb Dunbar,Susan Buchbinder,Theresa Wagner,Reese Isbell,Victoria Chinnell,Jin Bae,Gina Escamilla,Jenny Tseng,Ramey Fair,Shelly Ramirez,Gail Broder,Liz Briesemeister,Adi Ferrara +34 more
TL;DR: An attenuated replication-competent rVSV gag vaccine has an acceptable safety profile in healthy adults and is a promising new vaccine platform for the development of vaccines to combat HIV-1 and other serious human diseases.
Journal ArticleDOI
Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s.
Hernan Valdez,Ronald T. Mitsuyasu,Alan L. Landay,Anne Sevin,Ellen S. Chan,John Spritzler,Spyros A. Kalams,Richard B. Pollard,John L. Fahey,Lawrence Fox,Ann Namkung,Scharla Estep,Ronald B. Moss,David Sahner,Michael M. Lederman +14 more
TL;DR: In this paper, a human immunodeficiency virus (HIV)-infected patients who had received highly active antiretroviral therapy (HAART) or HAART and IL-2 for at least 60 weeks were immunized with tetanus toxoid, inactivated glycoprotein 120-depleted HIV-1, and hepatitis A and B vaccines.
Journal ArticleDOI
Safety and Immunogenicity of an HIV-1 Recombinant Canarypox Vaccine in Newborns and Infants of HIV-1–Infected Women
Dan L. Johnson,Elizabeth J. McFarland,Petronella Muresan,Terence Fenton,James McNamara,Jennifer S. Read,Elizabeth Hawkins,Pamela Bouquin,Scharla Estep,Georgia D. Tomaras,Carol Vincent,Mobeen H. Rathore,Ann J. Melvin,Sanjay Gurunathan,John S. Lambert +14 more
TL;DR: In children, vCP205 appeared to be safe and immunogenic and rare mucosal immunoglobulin A responses and no measurable vaccine-elicited serum antibodies were detected.
Lymphocyte Numbers but Does Not Enhance Responses to Immunization: Results of A5046s
Hernan Valdez,Ronald T. Mitsuyasu,Alan L. Landay,Anne Sevin,Ellen S. Chan,John Spritzler,Spyros A. Kalams,Richard B. Pollard,John L. Fahey,Lawrence Fox,Ann Namkung,Scharla Estep,Ronald B. Moss,David Sahner,Michael M. Lederman +14 more
TL;DR: To ascertain whether CD4(+) lymphocyte increases induced by interleukin (IL)-2 enhanced in vivo immune responses, 38 human immunodeficiency virus (HIV)-infected patients who had received highly active antiretroviral therapy or HAART and IL-2 for at least 60 weeks were immunized with tetanus toxoid, inactivated glycoprotein 120-depleted HIV-1, and hepatitis A and B vaccines.